Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

fresenius medical care deutschland gmbh, else kröner str.1, bad homburg, njemačka - kalcijev klorid dihidrat natrijev klorid natrijev hidrogenkarbonat magnezijev klorid heksahidrat glukoza hidrat - otopina za peritonejsku dijalizu - urbroj: otopina pripremljena za uporabu sadrži: kalcijev klorid dihidrat 0,1838 g/l, natrijev klorid 5,786 g/l, natrijev hidrogenkarbonat 2,940 g/l, magnezijev klorid heksahidrat 0,1017 g/l, glukoza hidrat 25,0 g/l (22,73 g glukoze), što odgovara iona ca2+ 1,25 mmol/l, iona na+ 134 mmol/l, iona mg 2+ 0,5 mmol/l, iona cl- 103,5 mmol/l, iona hco3- 34 mmol/l, glukoze 126,1 mmol/l.

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - биматопрост, timolol - glaucoma, open-angle; ocular hypertension - ophthalmologicals - smanjenje intraokularnog tlaka (iop) u bolesnika s otvorenim kutnim glaukom ili očne hipertenzije, koji nisu dovoljno osjetljivi na topikalne beta-blokatore ili prostaglandinske analoge.

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leukemija, limfocitna, kronična, b-stanica - antineoplastična sredstva - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - deksametazon - macular edema; uveitis - ophthalmologicals, other ophthalmologicals - Озурдекс indiciran za liječenje odraslih bolesnika s макулярным oticanjem nakon odvajanja mrežnice beča окклюзия (brvo) ili središnje vene mrežnice окклюзия (crvo). Озурдекс indiciran za liječenje odraslih bolesnika s upala stražnjeg segmenta oka, predstavljajući kao неинфекционный uveitis. Озурдекс indiciran za liječenje odraslih bolesnika s oštećenjem vida zbog dijabetes pomagala макулярного edema (ДМО), koji артифакии ili koga smatraju da je nedovoljno fleksibilan ili neprikladan za nepušače кортикостероидной terapija.

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - Омбитасвир, паритапревир, ritonavir - hepatitis c, kronični - antivirusni lijekovi za sustavnu uporabu - viekirax je indiciran u kombinaciji s drugim lijekovima za liječenje kroničnog hepatitisa c (chc) u odraslih. virus hepatitisa c (hcv) genotip određene aktivnosti .

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - hepatitis c, kronični - antivirusni lijekovi za sustavnu uporabu - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - imunosupresivi - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - atogepant - migrena poremećaja - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - leflunomid - arthritis, rheumatoid; arthritis, psoriatic - imunosupresivi - leflunomide indiciran za liječenje odraslih bolesnika s:aktivni reumatoidni artritis kao bolest-mijenjanje противоревматические lijekovi (dmards);aktivni psorijatični artritis. najnovije ili istodobno liječenje гепатотоксичными ili haematotoxic lijekovima (e. metotreksat) može dovesti do povećanog rizika od ozbiljnih nuspojava; stoga treba započeti liječenje leflunomidom pažljivo u vezi s tim aspektima koristi / rizika. osim toga, prebacivanje s лефлуномидом u drugi dmards bez vođenja postupka ispiranja također može povećati rizik od ozbiljnih nuspojava, čak i za dugo nakon komutacije.